Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 3, 2003, Pages 1104-1110

  Daniels, Julie T ^a   Cambrey, Alison D ^a   Occleston, Nicholas L ^a   Garrett, Qian ^a   Tarnuzzer, Roy W ^b   Schultz, Gregory S ^b   Khaw, Peng T ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF FLORIDA   (United States)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; GELATINASE A; ILOMASTAT; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCAR FORMATION; WOUND CONTRACTION; ZYMOGRAPHY;

EID: 0037334786     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0412     Document Type: Article

References (59)

1. Werb Z, Chin JR. Extracellular matrix remodelling during morphogenesis. Ann NY Acad Sci. 1998;857:110-118.
2. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behaviour. Annu Rev Cell Dev Biol. 2001;17:463-516.
3. Grinnell F. Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol. 1994;124:401-404.
4. Pilcher BK, Wang M, Qin XJ et al. Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Ann NY Acad Sci. 1999;878:12-24.
5. Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair (review). Int J Mol Med. 2000;4:391-407.
6. Clark RAF, Henson PM. The Molecular and Cellular Biology of Wound Repair. New York: Plenum Press; 1988.
7. AGIS Investigators. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000; 130:429-440.
8. Skuta GL, Beeson CC, Higginbotham EJ. Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk filtering surgery. Ophthalmology. 1992;99:438-444.
9. Fluorouracil Filtering Surgery Group. Five-year follow-up of the fluorouracil filtering surgery study. Am J Pathol. 1996;121:349-366.
10. Khaw PT, Ward S, Porter A, et al. The long-term effects of 5-fluorouracil and sodium butyrate on human Tenon's fibroblasts. Invest Ophthalmol Vis Sci. 1992;33:2043-2052.
11. Khaw PT, Sherwood MB, MacKay SL, et al. Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts. Arch Ophthalmol. 1992;110:1150-1154.
12. Khaw PT, Doyle JW, Sherwood MB, et al. Prolonged localized tissue effects from 5-minute exposures to fluorouracil and mitomycin C. Arch Ophthalmol. 1993;111:263-267.
13. Occleston NL, Daniels JT, Tarnuzzer RW, et al. Single exposures to antiproliferatives: long-term effects on ocular fibroblast wound-healing behaviour. Invest Ophthalmol Vis Sci. 1997;38:1998-2007.
14. Daniels JT, Occleston NL, Crowston JG, et al. Effects of antimetabolite induced cellular growth arrest on fibroblast-fibroblast interactions. Exp Eye Res. 1999;69:117-127.
15. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999;40:2225-2234.
16. Nagase H, Woessner F. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
17. Rudolph-Owen LA, Matrisian LM. Matrix metalloproteinases in remodelling of the normal and neoplastic mammary gland. J Mammary Gland Biol Neoplasia. 1998;2:177-189.
18. Fini ME, Cook JR, Mohan JJ. Proteolytic mechanisms in corneal ulceration and repair. Arch Dermatol Res. 1998;290:S12-S23.
19. Luttan A, Dewerchin M, Collen D, et al. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr A theroscler Rep. 2000;5:407-416.
20. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol. 1997;5:199-213.
21. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinase-3 (TIMP-3) in intestinal ulcerations. Am J Pathol. 1998;152:1005-1014.
22. Suomela S, Kariniemi AL, Snellman E, et al. Metalloelastase (MMP-12) and 92-kDa gelatinase (MMP-9) as well as their inhibitors, TIMP-1 and -3, are expressed in psoriatic lesions. Exp Dermatol. 2001;10:175-183.
23. Bendeck MP, Zempo N, Clowes AW, et al. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
24. Pauly RR, Passaniti A, Bilato C, et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994;75:41-54.
25. Leppert D, Hauser SL, Kishiyama JL, et al. Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J. 1995;9:1473-1481.
26. Leppert D, Waubant E, Galardy R, et al. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol. 1995; 154:4379-4389.
27. Romanic AM, Madri JA. The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol. 1994;125:1165-1178.
28. Nordstrom LA, Lochner J, Yeung W, et al. The metalloproteinase stromelysin-1 (transin) mediates PC12 cell growth cone invasiveness through basal laminae. Mol Cell Neurosci. 1995;6:56-68.
29. Nakagawa T, Kubota T, Kabuto M, et al. Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases. Anticancer Res. 1995;15:1985-1989.
30. Terada T, Okada Y, Nakanuma Y. Expression of matrix proteinases during human intrahepatic bile duct development: a possible role in biliary cell migration. Am J Pathol. 1995;147:1207-1213.
31. Scott KA, Wood EJ, Karran EH. A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction FEBS Lett. 1998;441:137-140.
32. Sheridan CM, Occleston NL, Hiscott P, et al. Matrix metalloproteinases: a role in the contraction of vitreo-retinal scar tissue. Am J Pathol. 2001;159:1555-1566.
33. Wong TTL, Mead AL, Khaw PT. Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2003;44:1097- 1103.
34. Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci USA. 1979;76: 1274-1278.
35. Mazure A, Grierson I. In vitro studies of the contractility of cell types involved in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1992;33:3407-3416.
36. Occleston NL, Alexander RA, Mazure A, et al. Effects of single exposures to antiproliferative agents on ocular fibroblast-mediated collagen contraction. Invest Ophthalmol Vis Sci. 1994;35:3681- 3690.
37. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
38. Tarnuzzer RW, Macauley SP, Farmerie WG, et al. Competitive RNA templates for detection and quantitation of growth factors, cytokines, extracellular matrix components and matrix metalloproteinases by RT-PCR. Biotechniques. 1996;20:670-674.
39. Ashcroft G, Herrick S, Tarnuzzer R, et al. Human ageing impairs injury-induced in vivo expression of tissue inhibitor of matrix metalloproteinases (TIMP)-1 and -2 proteins and mRNA. J Pathol. 1997;183:169-176.
40. Azzam HS, Thompson EW. Collagen-induced activation of the M(r) 72, 000 type IV collagenase in normal and malignant human fibroblastoid cells. Cancer Res. 1992;52:4540-4544.
41. Goldberg MA, Gaut CC, Bunn HF. Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events. Blood. 1991;77:271-277.
42. Nagase H, Suzuki K, Morodomi T, et al. Activation mechanisms of the precursors of matrix metalloproteinases 1, 2 and 3. Matrix Suppl. 1992;1:237-244.
43. Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry. 1992;31:7152-7154.
44. Davies B, Brown PD, East N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts [published correction appears in Cancer Res. 1993;53:3652]. Cancer Res. 1993;53:2087-2091.
45. Fini ME, Cui TY, Mouldovan A, et al. An inhibitor of the matrix metalloproteinases synthesized by rabbit corneal epithelium. Invest Ophthalmol Vis Sci. 1991;32:2997-3001.
46. Siggelkow H, Niedhart C, Kurre W, et al. In vitro differentiation potential of a new human osteosarcoma cell line (HOS 58). Differentiation. 1998;63:81-91.
47. Hunt SV. In: Kavovs GGB, ed. The Lymphocytes: a Practical Approach. Oxford, UK: IRL Press; 1987:1-35.
48. Harris AK, Stopak D, Wild P. Fibroblast traction as a mechanism for collagen morphogenesis. Nature. 1981;290:249-251.
49. Ehrlich HP, Rajaratnam JB. Cell locomotion forces versus cell contraction forces for collagen lattice contraction: an in vitro model of wound contraction. Tissue Cell. 1990;22:407-417.
50. Eastwood M, McGrouther DA, Brown RA. A culture force monitor for measurement of contraction forces generated in human dermal fibroblast cultures: evidence for cell-matrix mechanical signalling. Biochim Biophys Acta. 1994;1201:186-192.
51. Jeffrey JJ. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego, CA: Academic Press, Inc.; 1998:15-42.
52. Stephens P, Davies KJ, Occleston N, et al. Skin and oral fibroblasts exhibit phenotypic differences in extracellular matrix reorganisation and matrix metalloproteinase activity. Br J Dermatol. 2001; 144:229-237.
53. Davis GE, Pintar Allen KA, Salazar R, et al. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci. 2001;114:917-930.
54. Rittie L, Berton A, Monboisse JC, et al. Decreased contraction of glycated collagen lattices coincides with impaired matrix metalloproteinase production. Biocbem. Biophys Res Commun. 1999; 264:488-492.
55. Daniels JT, Occleston NL, Crowston JG, et al. Understanding and controlling the scarring response: the contribution of histology and microscopy. Microsc Res Tech. 1998;42:317-333.
56. Cordeiro MF, Chang L, Lim KS, et al. Modulating conjunctival wound healing. Eye. 2000;14:536-547.
57. Eastwood M, Porter R, Khan U, et al. Quantitative analysis of collagen gel contractile forces generated by dermal fibroblasts and the relationship to cell morphology. J Cell Physiol. 1996;166:33-42.
58. Jester JV, Petroll WM, Barry PA, et al. Temporal, 3-dimensional, cellular anatomy of corneal wound tissue. J Anat. 1995;186:301-311.
59. Olsen BR. In: Hay ED, ed. Cell Biology of Extracellular Matrix. New York: Plenum Press; 1991:177-220.